Biotech news for Tuesday, June 9, 2026, ranked by our 5-dimension investment framework — regulatory, technology, commercial, manufacturing, and narrative.
IDEAYA Biosciences ( IDYA ) has announced the pricing of an underwritten public offering to raise aggregate gross proceeds of approximately $300.0M, by selling 5.56M shares of common stock at a public offering price of $27.00 per share. IDEAYA Biosciences ( ID…
Wirestock GSK ( GSK ) is in talks to acquire oncology biotech Nuvalent ( NUVL ) for more than $9B, in what would be the British drugmaker’s largest acquisition in more than a decade, the Financial Times reported Tuesday. The companies have been in discussions…
Cibus ( CBUS ) Monday said that Craig Wichner, a board member since November 2025, has been appointed as the company’s CEO. Peter Beetham, who has served as the company’s interim CEO, will continue his role as the company’s president and COO. Wichner
matdesign24/iStock via Getty Images Merck ( MRK ) and Gilead Sciences ( GILD ) said that topline results from a pair of phase 3 trials of a combination pill containing the former's islatravir and the latter's lenacapavir met their primary endpoint. The two stu…
Savara ( SVRA ) said chief financial and administrative officer Dave Lowrance will step down effective July 15 for health-related reasons. The clinical-stage biopharmaceutical company said chief operating officer Robert Lutz will assume the additional role of…
Tango Therapeutics ( TNGX ) has launched an underwritten public offering of $500M of its common stock, the company said on Monday. Tango also intends to grant the underwriters a 30-day option to purchase up to an additional $75M of shares of its
IDEAYA Biosciences ( IDYA ) intends to offer and sell up to $300M of shares of its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to purchase its common stock in an underwritten public offering.
HHS, along with the State Department, on Monday released a statement that indicated the federal government may challenge cancer hazard assessments issued by the International Agency for Research on Cancer. The reasoning, according to the agencies, is because "…
Tango Therapeutics ( TNGX ) is up ~32% in Monday morning trading after posting initial data from a phase 1/2 trial of vopimetostat in combination with Revolution Medicines' ( RVMD ) daraxonrasib or zoldonrasib in pancreatic cancer. Second or third-line patient…
courtneyk Stock futures rose Monday, reversing early losses despite a jump in oil prices driven by renewed military strikes between Israel and Iran. Tech stocks led the rebound as major chipmakers stabilized, helping Wall Street move past early worries about a…
Galmed Pharmaceuticals ( GLMD ) has signed a definitive agreement to acquire Colospan, a commercial-stage medical device developer focused on colorectal surgery. Upon closing, Colospan will become a wholly owned subsidiary of Galmed. Colospan's lead product, t…
Caris Life Sciences ( CAI ) announced that its board of directors has approved a share repurchase program of up to $100M. CAI shares up 3.2% premarket. More on Caris Life Sciences, Inc. Caris Life Sciences, Inc. (CAI) Presents at Bank of America Global Healthc…
eXoZymes ( EXOZ ) priced a public offering of 296,135 units at $18/unit, with each unit consisting of 2 common shares and 1 warrant. The offering includes 592,270 common shares and 296,135 warrants, expected to generate ~$5.33M in gross proceeds. The transacti…
Incyte ( INCY ) has entered into a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for $1.25B. Star Therapeutics will be eligible to receive up to $750M in additional payments upon the achievement of sales mil…
Shares of Zealand Pharma ( ZLDPF ), the weight-loss drug developer, tumbled as much as 26% on Monday after fresh data from its experimental treatment sparked concerns about possible side effects. The Danish drugmaker said that while its drug survodutide met
Nurix Therapeutics ( NRIX ) shares surged on Monday after the company entered a global collaboration and licensing agreement with Roche ( RHHBY ) to develop and commercialize bexobrutideg, a potential best-in-class oral BTK degrader, in a deal worth up to $3B,…
Maskot Alvotech ( ALVO ) shares rose in premarket trading on Monday after the company said the U.S. Food and Drug Administration accepted for review its Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio (vedolizumab) for…